Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
Contact
BC 9, Batiment A 4eme etage
4 Place Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
stocks
Will Australia’s dwindling fuel supplies impact this share?
Australia’s petrol reserves have dropped from 60 to 35 days.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.20 | 4.30 | -0.05% |
| CAC 40 | 7,908.74 | 53.65 | -0.67% |
| DAX 40 | 22,921.59 | 246.49 | -1.06% |
| Dow JONES (US) | 46,552.72 | 117.16 | -0.25% |
| FTSE 100 | 10,348.79 | 87.50 | -0.84% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,977.19 | 19.15 | -0.09% |
| Nikkei 225 | 53,429.56 | 15.88 | 0.03% |
| NZX 50 Index | 13,069.66 | 167.51 | 1.30% |
| S&P 500 | 6,608.31 | 3.52 | -0.05% |
| S&P/ASX 200 | 8,728.80 | 1.50 | -0.02% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |